During the last few decades, mortality and morbidity of community-acquired meningitis in adult patients have improved in developed countries. Whereas more than a decade ago, mortality rates were 25%,1,2 case fatality rates are now in the range of 6% to 17% in most studies.3–5 One important factor that has contributed to the improved mortality and reduced morbidity has been the introduction of corticosteroids as adjunctive therapy in pneumococcal meningitis.6 The facts that a substantial proportion of patients do not survive bacterial meningitis and a large number of survivors have neurologic sequelae indicate that there is room for improvement.
from Neurology recent issues http://bit.ly/2JKMTSG
Comments
Post a Comment